Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

• Status: Recruiting
• Trial end date: 2024-11-15

Summary

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.

• Phase: Phase 3

Details

• Lead Sponsor: Daiichi Sankyo, Inc.
• Collaborator: AstraZeneca
• Treatments: Paclitaxel; Ramucirumab; Trastuzumab